Sort   by:  
 Page size 
UnknownHumoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
Not available
S-EPMC3415680 | biostudies-literature
UnknownA phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors.
Not available
S-EPMC4937525 | biostudies-literature
UnknownCombination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Not available
S-EPMC9869131 | biostudies-literature
UnknownThe trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Not available
S-EPMC2958458 | biostudies-literature
Sort   by:  
 Page size